Researchers discovered that SARS-CoV-2-specific T and B cells in long COVID patients are maintained for two years, similar to fully recovered individuals, offering insights into long-term immunity.

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of ...

The CD8+ T cell activation involves two key interactions: The TCR/pMHCI interaction: determines antigen specificity. Promiscuity is a characteristic feature of this interaction and it is essential for ...

The decrease in CD4 cells during HIV infection seems to be ... and higher LPS levels were associated with greater activation of CD8 + lymphocytes. CD8 + activation also was found to be higher ...

The treatment with recombinant antibodies and more recently T cell receptor (TCR) engineered T-cell therapies represent two immunological strategies that came into the forefront of clinical interest ...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

These early studies also revealed what was then a very surprising finding; i.e., that one type of tumor antigen-specific T cells (CD4+) can not only help the type of T cells (CD8+) that are best ...

ACTengine® IMA203 TCR-T is currently being evaluated in a ... thereby leveraging the power of both CD4+ and CD8+ T cells. As previously reported, IMA203 in combination with an immune checkpoint ...

Most HIV-negative adults have between 500 and 1500 CD4 cells in a cubic millimeter of blood. However, due to natural variation some people may have a CD4 count slightly outside the general range. It ...

TCR signal strength defines distinct mechanisms of T cell ... “Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase.” (2010) Journal of Experimental ...